NO306194B1 - Tolags fosfolipidvesikkel, fremgangsmåte til fremstilling og anvendelse derav, samt farmasöytisk preparat som omfatter vesikkelen - Google Patents

Tolags fosfolipidvesikkel, fremgangsmåte til fremstilling og anvendelse derav, samt farmasöytisk preparat som omfatter vesikkelen Download PDF

Info

Publication number
NO306194B1
NO306194B1 NO923703A NO923703A NO306194B1 NO 306194 B1 NO306194 B1 NO 306194B1 NO 923703 A NO923703 A NO 923703A NO 923703 A NO923703 A NO 923703A NO 306194 B1 NO306194 B1 NO 306194B1
Authority
NO
Norway
Prior art keywords
membrane
accordance
weight
phospholipid
vesicles
Prior art date
Application number
NO923703A
Other languages
English (en)
Norwegian (no)
Other versions
NO923703D0 (no
NO923703L (no
Inventor
Reinhard Glueck
Peter Klein
Peter Hermann
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of NO923703D0 publication Critical patent/NO923703D0/no
Publication of NO923703L publication Critical patent/NO923703L/no
Publication of NO306194B1 publication Critical patent/NO306194B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Feedback Control In General (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Air Conditioning Control Device (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
NO923703A 1991-02-02 1992-09-24 Tolags fosfolipidvesikkel, fremgangsmåte til fremstilling og anvendelse derav, samt farmasöytisk preparat som omfatter vesikkelen NO306194B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91101414A EP0497997B1 (en) 1991-02-02 1991-02-02 Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
PCT/EP1992/000089 WO1992013525A1 (en) 1991-02-02 1992-01-17 Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems

Publications (3)

Publication Number Publication Date
NO923703D0 NO923703D0 (no) 1992-09-24
NO923703L NO923703L (no) 1992-11-26
NO306194B1 true NO306194B1 (no) 1999-10-04

Family

ID=8206362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923703A NO306194B1 (no) 1991-02-02 1992-09-24 Tolags fosfolipidvesikkel, fremgangsmåte til fremstilling og anvendelse derav, samt farmasöytisk preparat som omfatter vesikkelen

Country Status (22)

Country Link
US (1) US6040167A (pt)
EP (1) EP0497997B1 (pt)
JP (1) JP3404037B2 (pt)
KR (1) KR100205693B1 (pt)
AT (1) ATE125154T1 (pt)
AU (1) AU657730B2 (pt)
BG (1) BG61215B1 (pt)
BR (1) BR9204116A (pt)
CA (1) CA2079685C (pt)
DE (1) DE69111414T2 (pt)
DK (1) DK0497997T3 (pt)
ES (1) ES2077086T3 (pt)
FI (1) FI109969B (pt)
GE (1) GEP20002229B (pt)
GR (1) GR3017490T3 (pt)
HK (1) HK56696A (pt)
HU (1) HU215533B (pt)
NO (1) NO306194B1 (pt)
PL (2) PL296382A1 (pt)
RO (1) RO114736B1 (pt)
RU (1) RU2125868C1 (pt)
WO (1) WO1992013525A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603872A (en) * 1991-02-14 1997-02-18 Baxter International Inc. Method of binding recognizing substances to liposomes
JP3407072B2 (ja) * 1991-02-14 2003-05-19 バクスター、インターナショナル、インコーポレイテッド リポソームへの認識物質の結合
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
ATE223701T1 (de) * 1994-05-31 2002-09-15 Inex Pharmaceutical Corp Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
AU6691496A (en) * 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
HUP9901790A3 (en) * 1996-05-08 2010-11-29 Nika Health Products Ltd Cationic virosomes as transfer system for genetic material
US7148324B1 (en) 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
CA2353816C (en) * 1998-12-14 2010-06-01 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation
JP2004513059A (ja) 1998-12-24 2004-04-30 ユセベ,ソシエテ アノニム ペプチド産物、方法及び組成物
ATE258428T1 (de) * 1999-10-08 2004-02-15 Nika Health Products Ltd Kationische dosper virosomen
BR0016472A (pt) * 1999-12-17 2002-08-20 Cápsula de ignição indutivamente ativável para sistemas de retenção de ocupantes de assento
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
DK1499294T3 (da) * 2002-04-29 2010-12-06 Biotesys Gmbh Polymeriserede, peptid-modificerede lipider som biologiske transportsystemer til mikronæringsstoffer
EP1447080A1 (en) * 2003-02-13 2004-08-18 Bestewil Holding B.V. Method for producing virosome-like particles
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
KR101376895B1 (ko) 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
JP5606067B2 (ja) 2006-09-15 2014-10-15 オタワ ホスピタル リサーチ インスティテュート 腫瘍崩壊性ラブドウイルス
CA3001467A1 (en) 2015-10-16 2017-04-20 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4790987A (en) * 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
IL86650A0 (en) * 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
WO1991003258A1 (en) * 1989-09-01 1991-03-21 Board Of Regents, The University Of Texas System Immunoliposomes for transmittal of activating signals to cells
AU652778B2 (en) * 1990-10-15 1994-09-08 Quest International B.V. Treatment composition

Also Published As

Publication number Publication date
CA2079685C (en) 2001-11-27
NO923703D0 (no) 1992-09-24
ATE125154T1 (de) 1995-08-15
ES2077086T3 (es) 1995-11-16
HU9203141D0 (en) 1992-12-28
FI924418A0 (fi) 1992-10-01
DE69111414T2 (de) 1996-02-01
GR3017490T3 (en) 1995-12-31
RU2125868C1 (ru) 1999-02-10
DK0497997T3 (da) 1995-11-27
BR9204116A (pt) 1993-06-08
EP0497997B1 (en) 1995-07-19
AU1169392A (en) 1992-09-07
BG61215B1 (en) 1997-03-31
PL296382A1 (en) 1993-11-02
JP3404037B2 (ja) 2003-05-06
FI924418A (fi) 1993-04-03
NO923703L (no) 1992-11-26
US6040167A (en) 2000-03-21
PL170169B1 (en) 1996-10-31
RO114736B1 (ro) 1999-07-30
HUT66194A (en) 1994-10-28
HK56696A (en) 1996-04-12
HU215533B (hu) 1999-01-28
DE69111414D1 (de) 1995-08-24
FI109969B (fi) 2002-11-15
KR100205693B1 (en) 1999-07-01
WO1992013525A1 (en) 1992-08-20
AU657730B2 (en) 1995-03-23
BG96928A (bg) 1994-03-24
CA2079685A1 (en) 1992-08-03
EP0497997A1 (en) 1992-08-12
GEP20002229B (en) 2000-09-25
JPH05505406A (ja) 1993-08-12

Similar Documents

Publication Publication Date Title
NO306194B1 (no) Tolags fosfolipidvesikkel, fremgangsmåte til fremstilling og anvendelse derav, samt farmasöytisk preparat som omfatter vesikkelen
Nisini et al. The multirole of liposomes in therapy and prevention of infectious diseases
Espuelas et al. Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes
Huckriede et al. Influenza virosomes in vaccine development
DE69229703T2 (de) Wiederhergestellte Influenza-Virosomen mit immunostimulierenden und immunoverstärkenden Eigenschaften und diese enthaltende Impfstoffe
H. Ucisik et al. Emulsomes meet S-layer proteins: an emerging targeted drug delivery system
TWI672149B (zh) 改良之疫苗組成物及使用方法
US4148876A (en) Biological preparations
US10159729B2 (en) Antigen and method for production thereof
KR101290475B1 (ko) 인플루엔자 바이러스 및 비형 간염 바이러스로부터의항원을 포함하는 비로좀 입자
Tiwari et al. Viral protein complexed liposomes for intranasal delivery of hepatitis B surface antigen
Bhattacharya et al. Virosomes: A novel strategy for drug delivery and targeting
CA1079634A (en) Antigens bound to exterior surface of microvesicles
de Jonge et al. Use of a dialyzable short-chain phospholipid for efficient solubilization and reconstitution of influenza virus envelopes
Ali et al. Virosome: An engineered virus for vaccine delivery
Park et al. Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles
US20160256388A1 (en) Compositions and methods for treatment of respiratory tract infections
Rathore et al. Virosomes: a novel vaccination technology
Garnier et al. Enhancement of in vivo and in vitro T cell response against measles virus haemagglutinin after its incorporation into liposomes: effect of the phospholipid composition
DE69127975T2 (de) Impfstoffe
Metcalfe et al. Virosomes for vaccine delivery
HU219353B (en) Synthetic membrane vesicles as vehicles containing functionally active fusional peptides and pharmaceutical compositions comprising them
EP4108251A1 (en) Griffithsin for use in a method of preventing or treating infections with respiratory viruses
Fand et al. VIROSOMES AS AN INNOVATIVE DRUG DELIVERY SYSTEM
Sugahara et al. Preparation of cationic immunovesicles containing cationic peptide lipid for specific drug delivery to target cells

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees